Financial Performance - The company achieved a revenue of CNY 100.21 million for the reporting period, representing a growth rate of 55.71%[6] - The net profit for the period was CNY 9.21 million, with a growth rate of 55.34%[6] - The product gross margin stood at 78.75%[6] - The company's operating revenue for the current period reached ¥100,209,522.13, representing a 55.71% increase compared to ¥64,357,584.88 in the same period last year[27] - The net profit attributable to shareholders of the listed company was ¥9,214,296.31, a 55.34% increase from ¥5,931,728.13 year-on-year[27] - The total assets increased by 24.84% to ¥1,165,299,743.46 from ¥933,400,392.16 at the end of the previous year[28] - The net profit after deducting non-recurring gains and losses was 7.29 million yuan, up 47.45% year-on-year[48] - The company reported a basic earnings per share of ¥0.08, up 60.00% from ¥0.05 in the same period last year[27] Clinical Development - The company successfully completed a Phase III clinical trial for its human interferon α1b nebulized inhalation treatment for respiratory syncytial virus lower respiratory tract infections in children[6] - The company completed the phase III clinical trial for human interferon α1b for treating RSV pneumonia, showing significant clinical benefits[50] - The company initiated a phase III clinical trial for human interferon α1b for COVID-19, with 62 patients enrolled as of the reporting period[51] - The Phase III clinical trial for human interferon α1b aerosol inhalation treatment for pediatric RSV pneumonia has shown positive results, significantly reducing clinical symptom duration by nearly one day within 72 hours of treatment[177] - The company has initiated a Phase III clinical trial for human interferon α1b for the prevention and early treatment of COVID-19, adding 10 new clinical centers and enrolling 62 COVID-19 patients during the reporting period[177] Research and Development - The company is developing a new type of PEG-integrated interferon mutant injection, which combines long-acting and high-efficiency properties[15] - The company is focusing on expanding its clinical applications in oncology, particularly with its main product, γδT cell therapy, which shows synergistic effects with interferon α1b[89] - The γδT cell tumor immunotherapy project has improved the expansion factor of γδT cells from 450 to 16,000 times, significantly increasing the yield of cell preparations for clinical research[116] - Research and development expenses amounted to ¥6,245,500.90, which is 6.23% of total revenue, showing a 7.73% increase from the previous year[73] Market Position and Strategy - The company has a leading market share in the Chinese interferon market, with its product, Yundesu®, being a well-established brand[34] - The company is focused on expanding its innovative drug products to compete in the international market[6] - The company is actively exploring new market segments for its flagship product, human interferon α1b, to meet growing clinical demands[102] - The company successfully won the bid for interferon α1b powder injection in the multi-province alliance procurement led by Guangdong Province, resulting in rapid growth in hospital coverage and sales in the alliance area, significantly increasing market share[64] Financial Position and Assets - The company's total net assets at the end of the period were CNY 586 million[6] - The company's debt-to-asset ratio (consolidated) rose to 49.68% from 38.42% year-on-year[28] - The total liabilities rose to CNY 578,936,142.33 from CNY 358,586,812.34, marking an increase of around 61.5%[145] - The company’s long-term borrowings rose by 57.49% to 311,452,432.28 yuan, attributed to new loans for the intelligent production and R&D base project[70] Corporate Governance and Recognition - The company was awarded the title of "2022 China's Preferred Employer" by Peking University and Zhaopin, enhancing its employer brand recognition[5] - The company has been recognized as a "high-tech enterprise" and a "national intellectual property demonstration enterprise"[47] - The company has established a corporate governance structure including a shareholders' meeting, board of directors, and supervisory board[180] Environmental and Social Responsibility - The company emphasizes environmental protection and sustainable development, with new facilities designed to meet higher standards for energy conservation and emissions reduction[45] - The company has established a sewage treatment station to handle wastewater generated during production, ensuring compliance with environmental regulations[99] - The company actively engages in social responsibility initiatives, focusing on ESG principles and enhancing its governance structure[90][93] Workforce and Talent Development - The company has increased its total workforce by 20%, with 45% of new hires being sales personnel, ensuring a robust talent pipeline for innovation and marketing strategies[54] - The number of sales personnel increased from 76 to 110, reflecting a growth of 44.74%[136] - The company has a total of 10,919,016 shares held by directors and senior management, representing 8.9640% of total shares[131] Future Outlook - The company aims to maintain a strong growth momentum and create greater value for investors in the second half of 2023[48] - The company anticipates continued growth opportunities in the biopharmaceutical industry, driven by national support for health and pharmaceutical development[66] - The biopharmaceutical sector is anticipated to enter a new phase of growth, driven by increased investment in research and development and a shift from sales-driven to innovation-driven strategies among companies[58]

证券代码：837344 证券简称：三元基因 公告编号：2023-028 北京三元基因药业股份有限公司 2022 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 北京三元基因药业股份有限公司（以下简称"公司"）于 2023 年 4 月 21 日在北京证券交易所官网（www.bse.cn）披露了《北京三元基 因药业股份有限公司 2022 年年度报告》（公告编号：2023-005），为 方便广大投资者更深入了解公司 2022 年年度经营业绩的具体情况， 公司拟召开 2022 年年度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 5 月 11 日（星期四）15:00-17:00。 （二）会议召开地点 本次年度报告业绩说明会将采用网络远程的方式举行，投资者可 登陆全景网"投资者关系互动平台"（http://ir.p5w.net）和中证路演中 心（https://www.cs.com.cn/roadshow）参与本次年度业绩说明会。 ...

Financial Performance - Operating revenue for Q1 2023 was ¥34,376,162.80, reflecting a growth of 15.79% from ¥29,687,302.57 in Q1 2022[9] - Net profit attributable to shareholders decreased by 47.64% to ¥1,755,211.84 from ¥3,351,979.41 in the same period last year[9] - Total operating revenue for Q1 2023 reached ¥34,376,162.80, an increase from ¥29,687,302.57 in Q1 2022, representing a growth of approximately 15.7%[44] - Total operating costs for Q1 2023 were ¥32,475,766.48, up from ¥26,403,718.80 in Q1 2022, indicating an increase of about 22.5%[45] - Net profit for Q1 2023 was ¥1,755,211.84, a decrease from ¥3,351,979.41 in Q1 2022, reflecting a decline of approximately 47.6%[46] - Basic earnings per share for Q1 2023 were ¥0.01, down from ¥0.03 in Q1 2022[46] - Operating profit decreased to ¥2,301,716.04 from ¥3,951,638.70, a decline of about 41.8% compared to the previous year[49] - Net profit fell to ¥1,944,087.48 from ¥3,321,937.41, reflecting a decrease of approximately 41.3% year-over-year[50] - Basic and diluted earnings per share decreased to ¥0.02 from ¥0.03, a reduction of 33.3%[50] - Total comprehensive income amounted to ¥1,944,087.48, down from ¥3,321,937.41, indicating a decrease of about 41.3% year-over-year[50] Assets and Liabilities - Total assets as of March 31, 2023, reached ¥1,091,009,008.52, an increase of 16.89% compared to ¥933,400,392.16 at the end of 2022[9] - The company’s total liabilities to assets ratio increased to 47.05% from 38.42% year-over-year[9] - The company's total liabilities as of March 31, 2023, were ¥513,272,354.36, compared to ¥358,586,812.34 at the end of 2022[38] - The company's short-term borrowings increased to ¥26,531,524.32 as of March 31, 2023, from ¥13,831,518.24 at the end of 2022[37] - Total liabilities increased to ¥510,904,300.77 from ¥356,294,927.75, representing a rise of approximately 43.2%[42] - Current assets totaled ¥356,202,806.54, up from ¥347,954,594.37, showing a growth of about 2.1%[42] - Non-current assets increased to ¥753,699,534.73 from ¥604,226,423.90, indicating a growth of approximately 24.7%[42] - Long-term borrowings increased to ¥261,366,262.09 from ¥197,765,198.13, representing a growth of approximately 32.2%[42] Cash Flow - The net cash flow from operating activities was negative at -¥11,418,275.87, a decline of 180.53% compared to ¥14,178,778.03 in Q1 2022[10] - Cash flow from operating activities showed a net outflow of ¥11,418,275.87, compared to a net inflow of ¥14,178,778.03 in the same period last year[51] - Cash flow from investing activities resulted in a net outflow of ¥108,461,515.10, significantly higher than the outflow of ¥41,277,062.39 in the previous year[52] - Cash flow from financing activities generated a net inflow of ¥74,976,977.25, contrasting with a net outflow of ¥1,233,195.61 in the same period last year[52] - The ending cash and cash equivalents balance decreased to ¥180,526,369.49 from ¥225,429,183.21 at the end of 2022[36] - The ending cash and cash equivalents balance decreased to $175,181,373.76 from $244,282,490.73[55] - The company experienced a net decrease in cash and cash equivalents of -$41,841,821.74 compared to -$28,713,615.61 previously[55] Investments and R&D - The balance of construction in progress increased by 51.18% to ¥13,701.34 million, driven by the development of an intelligent R&D and production base for gene engineering drugs[11] - Investment activities saw a cash outflow increase of 162.76%, totaling ¥6,718.45 million, primarily for various R&D projects[17] - R&D expenses increased to ¥2,518,540.70 from ¥2,123,768.92, representing a growth of approximately 18.6% year-over-year[49] - The company is advancing its Phase III clinical trials for human interferon α1b nebulized inhalation treatment for pediatric RSV pneumonia, having completed work at 33 clinical research centers[32] - For the Phase III clinical trial of human interferon α1b for COVID-19 pneumonia, the company has added 8 new clinical research centers and received ethical approval for 9 centers, bringing the total to 15[32] - The company has completed the enrollment and follow-up of 19 cases for the Phase II/III adaptive clinical trial of a new PEG-integrated interferon mutant injection for hepatitis B[32] Shareholder Information - The total number of unrestricted shares is 113,560,796, representing 93.23% of the total share capital[21] - The total share capital is 121,810,000 shares, with 6,837 common shareholders[21] - The largest shareholder, Beijing Southeast Pharmaceutical Investment Holding Co., Ltd., holds 46,907,925 shares, accounting for 38.51% of the total shares[22] - The total number of restricted shares is 8,249,204, representing 6.77% of the total share capital[21] Compliance and Governance - The company has strictly adhered to commitments made during its public offering process, with no violations reported[30] - The company has not engaged in any litigation, arbitration, or external guarantees during the reporting period[27] - The stock option grant results for the 2022 stock incentive plan have been completed and announced[28] Construction and Development - The company has completed the construction of the main structure of its new gene engineering drug production and R&D base, which is part of a key project in Beijing[31] - The company has initiated the installation of purification and engineering equipment in its production workshop and R&D center[31] - The company has initiated civil construction for wastewater treatment and security facilities at its new site[31] Financial Expenses - Financial expenses rose by 44.91% due to increased interest expenses from short-term loans[16] - The company reported a significant increase in financial expenses, with interest expenses rising to ¥193,042.65 from ¥89,195.61, an increase of approximately 116.5%[49]

Financial Performance - In 2022, the company achieved a revenue of 170 million yuan and a net profit of over 31 million yuan, with an operating cash flow of over 68.61 million yuan[6]. - The company's operating revenue for 2022 was ¥170,998,937.09, a decrease of 15.18% compared to ¥201,604,942.27 in 2021[34]. - The net profit attributable to shareholders for 2022 was ¥31,058,696.22, down 23.15% from ¥40,414,576.19 in 2021[34]. - The cash flow from operating activities for 2022 was ¥68,618,602.80, representing a 60.53% increase from ¥42,745,631.37 in 2021[37]. - The company reported a basic earnings per share of ¥0.25 for 2022, a decrease of 24.24% from ¥0.33 in 2021[34]. - The weighted average return on equity (ROE) was 5.56% for 2022, down from 7.57% in 2021[34]. - The company achieved a net non-operating profit of 10,339,578.81 in 2022, compared to 7,604,684.70 in 2021, indicating a growth in profitability[44]. - The company reported a significant increase in non-operating income, rising by 8,271,772.50% to ¥33.09 thousand in 2022[87]. - The total investment cash flow for 2022 was negative at approximately -¥323.19 million, an increase in outflow of 541.39% compared to the previous year[101]. - The company has cumulatively distributed dividends exceeding ¥130 million to all shareholders[151]. Research and Development - The company has established four major technology platforms to support continuous innovation and development in drug production[52]. - The company is focused on developing a new PEG-integrated interferon mutant injection, which aims to combine long-acting properties with high efficacy and safety[21]. - The company has invested in innovative clinical operation models to enhance the quality and efficiency of clinical research amid challenges posed by the pandemic[54]. - The company is conducting a Phase III clinical trial for human interferon α1b to treat COVID-19, collaborating with 27 designated treatment centers across the country, with 7 centers completing project initiation and 6 centers obtaining ethical approval[56]. - The company is working on a gene screening chip to predict the efficacy of interferon therapy for hepatitis B patients, which aligns with global treatment guidelines and could create significant economic benefits[117]. - The company is enhancing the production process of human interferon α1b to improve quality and reduce costs, which is crucial for maintaining competitive advantages[118]. - The company has increased R&D investment to over 50 million yuan annually, with four major new drug projects reaching critical milestones[150]. - The company has a strong R&D team and has established an independent R&D and medical department to focus on biotechnological product development[77]. - The total number of R&D personnel increased from 38 to 44, with the proportion of R&D staff to total employees rising from 17.92% to 19.21%[114]. Market Position and Competition - The company’s main product, human interferon α1b, significantly contributes to its revenue, with a high market demand due to its clinical efficacy[13]. - The company’s human interferon α1b product has a broad clinical application, covering multiple medical fields including hepatology, infectious diseases, pediatrics, and oncology[50]. - The company’s main product, human interferon α1b, has maintained a leading market share in China, covering over 5,000 medical institutions across more than 30 provinces[48]. - The company faces risks related to accounts receivable management and industry competition, particularly in the biopharmaceutical sector[12]. - The company’s main product, human interferon α1b, significantly contributes to its revenue, but faces competition risks from new entrants and better clinical alternatives[158]. Intellectual Property and Innovation - The company holds a total of 52 invention patents in countries including China, the United States, and Japan as of the end of the reporting period[5]. - The company was recognized as a "National Intellectual Property Demonstration Enterprise" by the National Intellectual Property Administration in October 2022[6]. - The company has successfully developed the first gene-engineered drug with independent intellectual property rights in China, human interferon α1b, and established four major technology platforms for future innovation[66]. - The company has established a credit control system to manage accounts receivable effectively, especially for commercial distribution channels[155]. Clinical Trials and Product Development - The company completed the Phase III clinical trial for inhaled interferon α1b treatment for pediatric respiratory syncytial virus pneumonia, with all cases enrolled and clinical observations completed[5]. - The company has completed the Phase III clinical trial as planned, preparing for the registration application for the nebulized treatment[55]. - The company is in the final stage of clinical trials for the human interferon α1b project, which aims to revise the product description to include nebulized inhalation as a delivery method[116]. - The company is developing a pediatric RSV pneumonia inhalation agent, which is expected to significantly enhance performance and maintain long-term competitive advantages in a large market[117]. - The γδT cell therapy project has shown promising safety results, with 10 liver cancer patients observed for over six months without serious adverse reactions[59]. Financial Management and Investments - Total assets increased by 43.54% to ¥933,400,392.16 in 2022, compared to ¥650,273,778.58 in 2021[35]. - Total liabilities surged by 234.81% to ¥358,586,812.34 in 2022, up from ¥107,102,826.23 in 2021[35]. - The company has a strong focus on high-quality development, overcoming challenges posed by the COVID-19 pandemic while advancing its drug development projects[65]. - The company has decided not to distribute profits for the fiscal year 2022, despite having positive earnings and undistributed profits, to support ongoing investments in new plant construction and product development[199]. Corporate Governance and Compliance - The company has established a robust corporate governance structure, complying with relevant laws and regulations since its listing on the Beijing Stock Exchange on November 15, 2021[131]. - The company emphasizes investor relations management, ensuring timely and accurate information disclosure, with no instances of overdue disclosures reported[132]. - The company has implemented a comprehensive safety management system, achieving a "zero" accident goal in production safety[129]. - The company actively integrates ESG principles into its operations, focusing on environmental, social, and governance performance[126]. Strategic Development and Future Outlook - The company is positioned to leverage opportunities in the pharmaceutical industry, particularly in children's medication and innovative drug development[78]. - The company is currently in a critical phase of new product research and development, which is a key factor in the decision to withhold profit distribution[199]. - The company is prioritizing investments in technology and market expansion as part of its long-term strategy[199]. - The overall focus remains on enhancing shareholder value through strategic investments rather than immediate profit sharing[199].

Financial Performance - The company's operating revenue for 2022 was CNY 170,998,937.09, a decrease of 15.18% compared to CNY 201,604,942.27 in the previous year[4] - The net profit attributable to shareholders was CNY 31,789,003.35, down 21.34% from CNY 40,414,576.19 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 30,561,129.55, a decrease of 6.85% compared to CNY 32,809,891.49 in the previous year[4] - Basic earnings per share were CNY 0.26, down 21.21% from CNY 0.33 in the previous year[4] Assets and Equity - Total assets at the end of the reporting period were CNY 930,362,961.14, an increase of 43.07% from CNY 650,273,778.58 at the beginning of the period[5] - Shareholders' equity attributable to the company was CNY 575,543,886.95, up 5.96% from CNY 543,170,952.35 at the beginning of the period[5] Impact of Pandemic - The decrease in revenue and net profit was primarily due to the impact of the pandemic, which led to a significant reduction in patient visits to hospitals[6] - The company expects sales to gradually improve following the relaxation of pandemic policies in December, although overall revenue for the year still declined compared to the previous year[8] Future Outlook and Notes - The growth in total assets was mainly driven by the advancement of the intelligent production base project for gene engineering drugs and R&D fundraising projects[8] - Investors are advised to note that the financial data for 2022 is preliminary and subject to audit, which may result in discrepancies[9]

Financial Performance - In the first half of 2022, the company achieved operating revenue of 64.36 million yuan and a net profit of 5.93 million yuan, with a product gross margin of 80.08%[8] - The company's revenue for the reporting period was ¥64,357,584.88, a decrease of 13.42% compared to ¥74,331,152.94 in the same period last year[30] - The net profit attributable to shareholders was ¥5,931,728.13, reflecting a decline of 35.91% from ¥9,255,803.84 year-on-year[30] - The gross profit margin decreased to 80.08% from 81.61% in the previous year[30] - Basic earnings per share fell by 37.50% to ¥0.05 from ¥0.08 in the same period last year[30] - The weighted average return on net assets based on net profit attributable to shareholders was 1.09%, down from 1.75%[30] - The company reported a net profit of ¥4,945,987.42 after deducting non-recurring gains and losses, a slight increase of 1.24% from ¥4,885,631.81[30] - Net profit decreased by 35.91%, reflecting ongoing challenges in profitability[33] Assets and Liabilities - Total assets increased by 4.68% to ¥680,689,214.20 compared to the previous year[31] - Total liabilities rose by 22.86% to ¥131,586,533.72, indicating increased financial leverage[31] - The company's total assets at the end of the period amounted to 680,000,000.00 CNY, with cash and cash equivalents decreasing by 19.46% to 220,863,325.02 CNY[62] - Accounts receivable decreased by 23.10% to 69,721,550.44 CNY, while prepayments increased significantly by 335.56% to 14,298,857.85 CNY due to enhanced market promotion efforts[63] - Inventory increased by 32.22% to 26,899,145.49 CNY, attributed to strategic raw material reserves and domestic sourcing adjustments[64] - Total liabilities reached CNY 130,089,254.91, up from CNY 106,268,831.41, indicating a growth of 22.4%[145] Research and Development - The company emphasizes the importance of R&D and academic promotion in its strategic direction to maintain competitive advantages in the biopharmaceutical industry[7] - The company has established four major technology platforms to support ongoing innovation and development[42] - The company is pioneering clinical research on human interferon α1b for respiratory syncytial virus pneumonia and COVID-19[40] - The company has successfully developed a unique water injection formulation for human interferon α1b, enhancing its product stability[41] - The company is advancing four new drug development projects, including a Phase III clinical trial for inhaled interferon α1b for pediatric RSV pneumonia[49] - The company is also conducting a Phase III clinical trial for interferon α1b in treating COVID-19, with ongoing studies in both mainland China and Hong Kong[50] - The company has ongoing significant research and development expenditures related to clinical trials for interferon α1b, which are progressing smoothly[174] Market Position and Strategy - The company is focusing on a development path characterized by specialization, refinement, uniqueness, and innovation, aiming to become a high-quality development "specialized and innovative" enterprise[7] - The company’s main product, human interferon α1b, has a significant contribution to revenue, and the market demand for this product remains high due to its confirmed efficacy and broad clinical application[13] - The product "Yundesu®" (human interferon α1b) has a leading market share in China's interferon market[37] - The company is actively exploring new market segments for its main product, human interferon α1b, to meet the growing clinical demand[96] - The company has a comprehensive strategy to address market expansion risks by leveraging its brand value and focusing on differentiated product promotion[97] Financial Management - The company has signed a fixed asset loan agreement with a total amount of 470 million yuan, with a repayment period of 15 years, secured by land use rights and construction projects[14] - The company has a long-term loan repayment schedule, with a total outstanding balance of ¥65,503,495.98 as of the reporting period, which is manageable within its financial capabilities[100] - The company has implemented measures to mitigate accounts receivable risks, including strengthening management of drug distribution companies and establishing credit control systems[93] - The company has a robust internal control system to manage credit risks associated with its accounts receivable[93] Regulatory and Compliance - The company has secured 12 drug registration certificates, demonstrating compliance with stringent regulatory standards in the biopharmaceutical industry[45] - The company is committed to environmental protection, ensuring compliance with environmental laws and maintaining a robust environmental management system[88] - The company has received approval for the environmental impact report for the gene engineering drug production base project from the Beijing Daxing District Ecological Environment Bureau[89] Shareholder Information - The total share capital of the company is 121,810,000 shares[24] - The controlling shareholder is Beijing Southeast Pharmaceutical Investment Holding Co., Ltd.[25] - The largest shareholder, Beijing Southeast Medicine Investment Holding Co., Ltd., holds 46,907,925 shares, accounting for 38.51% of total shares[116] - The company’s total share capital remains at 121,810,000 shares, with 7,517 shareholders reported[113] Economic Environment - The pharmaceutical industry in China is experiencing growth due to increasing healthcare demands driven by an aging population and rising health awareness[55] - The government is actively supporting the biopharmaceutical industry, aiming to transition China from a major pharmaceutical country to a strong pharmaceutical country by 2030[57] - The macroeconomic environment for the pharmaceutical industry remains complex, with pressures from healthcare expenditure and policy reforms impacting operations[56] - The company aims to leverage the strategic opportunities presented by the government's support for the biopharmaceutical sector to enhance its market position[61]

Financial Performance - Operating revenue for the first quarter of 2022 was CNY 29,687,302.57, down 13.12% year-on-year[16] - Net profit attributable to shareholders for the first quarter of 2022 was CNY 3,351,979.41, an increase of 18.72% compared to the same period last year[16] - Basic earnings per share for the first quarter of 2022 were CNY 0.03, up 50.00% from CNY 0.02 in the previous year[16] - Total operating revenue for Q1 2022 was ¥29,687,302.57, a decrease of 13.5% from ¥34,171,109.14 in Q1 2021[43] - Net profit for Q1 2022 increased to ¥3,351,979.41, representing a growth of 18.7% compared to ¥2,823,376.49 in Q1 2021[45] - Operating profit for Q1 2022 was ¥3,908,239.93, an increase from ¥3,238,899.40 in Q1 2021[44] Assets and Liabilities - Total assets as of March 31, 2022, were CNY 633,768,796.90, a decrease of 2.54% compared to the end of the previous year[16] - The company's total liabilities to total assets ratio was 13.77% as of March 31, 2022, down from 16.47% at the end of the previous year[16] - Total liabilities decreased to CNY 87,245,865.14 from CNY 107,102,826.23, a reduction of 18.6%[37] - Total equity increased to CNY 546,522,931.76, up from CNY 543,170,952.35, reflecting a growth of 0.6%[37] - The total assets decreased to ¥655,806,914.15 from ¥671,514,340.21[41] - Total liabilities decreased to ¥87,239,467.94 in the latest reporting period, down from ¥106,268,831.41[41] Cash Flow - Net cash flow from operating activities increased by CNY 17,055,940.04, representing a growth of 592.80% compared to the previous year[17] - Cash inflows from operating activities reached CNY 56,961,110.72, up from CNY 42,777,401.41 year-over-year[50] - The net cash flow from operating activities was CNY 14,178,778.03, a recovery from a negative CNY 2,877,162.01 in the previous year[52] - The company reported a net cash outflow from financing activities of CNY 1,233,195.61, an improvement from negative CNY 7,546,414.36 last year[52] - The company experienced a net decrease in cash and cash equivalents of CNY 28,713,615.61, compared to a decrease of CNY 19,798,432.64 in the previous year[55] Shareholder Information - The registered capital of the company is CNY 121,810,000[14] - The total number of ordinary shareholders is 7,623[20] - The largest shareholder, Beijing Southeast Medicine Investment Holding Co., Ltd., holds 46,907,925 shares, representing 38.51% of total shares[22] - Zhejiang Shengda Technology Development Co., Ltd. is the second largest shareholder with 17,199,373 shares, accounting for 14.12%[22] - The total shares held by the top ten shareholders amount to 90,000,950, which is 73.89% of the total shares[22] Research and Development - The company is conducting a Phase III clinical trial for a drug targeting respiratory syncytial virus, with 190 subjects enrolled as of January 18, 2022[31] - The company has completed the first interim analysis of the clinical trial, with positive efficacy trends and good safety observed[31] - Research and development expenses decreased to ¥2,123,768.92 in Q1 2022, down 53.8% from ¥4,592,697.23 in Q1 2021[44] Compliance and Commitments - The company has complied with all commitments made during its public offering process, with no breaches reported[27] - The company has no ongoing litigation, external guarantees, or external loans during the reporting period[26] - The company has no profit distribution or capital increase from reserves during the reporting period[32] Asset Management - The company has pledged assets totaling 76,309,892.76 yuan, which represents 12.04% of total assets[29] - Current assets totaled CNY 360,672,150.71, a decrease of 10.5% from CNY 403,029,145.30 as of December 31, 2021[35] - Accounts receivable decreased to CNY 74,656,756.47 from CNY 90,665,072.86, representing a decline of 17.7%[35] - Inventory increased to CNY 25,894,154.27, up 27.0% from CNY 20,343,948.52[35] - Total non-current assets rose to CNY 273,096,646.19, an increase of 10.4% from CNY 247,244,633.28[36] - Cash and cash equivalents were CNY 245,884,230.48, down from CNY 274,215,710.45, a decrease of 10.3%[35]

Financial Performance - In 2021, the company achieved a revenue of 202 million RMB, with a net profit of 40.41 million RMB, representing a year-on-year growth of 12.38%[6] - The company's operating revenue for 2021 was CNY 201,604,942.27, representing a year-over-year increase of 9.67% compared to CNY 183,827,367.90 in 2020[35] - The net profit attributable to shareholders for 2021 was CNY 40,414,576.19, which is a 12.38% increase from CNY 35,963,788.73 in 2020[35] - The gross profit margin for 2021 was 81.01%, down from 84.00% in 2020[35] - The company's total revenue for the current period reached ¥201,604,942.27, representing a 9.67% increase compared to ¥183,827,367.90 in the same period last year[90] - The company's main business revenue reached ¥201,603,579.43, representing a year-on-year increase of 9.69%[95] Research and Development - The company is focused on developing new products, including a novel PEG-integrated interferon mutant injection, which aims to combine long-lasting effects with high efficacy and safety[22] - The company has established four key technology platforms, including a high stability protein solution technology platform and a novel interferon preparation technology platform, which have received multiple patents in China, the US, Japan, and South Korea[57] - The company is advancing the "γδT cell tumor immunotherapy clinical research" project and related product development, integrating the cell therapy industrialization platform into the construction of a new intelligent factory[72] - The company is actively developing new products, including nebulized inhalation formulations and PEG modification technologies, which are at the international leading level[150] - The company is conducting Phase III clinical trials for human interferon α1b for the treatment of RSV pneumonia in children, with over 80% of enrollment targets achieved across 28 clinical research centers[118] Market Position and Strategy - The company primarily engages in the research, development, production, and sales of biopharmaceuticals, with key products including interferon α1b formulations[28] - The company has developed a clear profit model primarily through the sales of human interferon α1b, which has maintained a leading market share in China's interferon market for several consecutive years[53] - The company is actively pursuing market expansion strategies to diversify its revenue streams and reduce dependency on a single product line[163] - The company is focusing on continuous innovation and brand enhancement, with four new drug R&D projects progressing well, positioning it for broader market opportunities[162] Financial Management - The company's cash flow from operating activities decreased by 39.40% to CNY 42,745,631.37 in 2021, down from CNY 70,535,446.29 in 2020[39] - The total assets increased by 10.43% to CNY 650,273,778.58 at the end of 2021, compared to CNY 588,864,751.51 at the beginning of the year[37] - Total liabilities rose significantly by 79.84% to CNY 107,102,826.23 at the end of 2021, compared to CNY 59,553,795.37 at the beginning of the year[37] - The company's asset-liability ratio (consolidated) was 16.47% at the end of 2021, up from 10.11% at the beginning of the year[37] Regulatory and Industry Environment - The pharmaceutical industry is highly regulated in China, with significant risks associated with policy changes that could impact operational strategies and market demands[17] - The National Healthcare Security Administration initiated a bulk procurement policy for insulin, expanding it to biological drugs, which may lead to significant price reductions and increased operational challenges for companies[17] - The pharmaceutical industry is expected to grow due to increasing healthcare demands driven by an aging population and enhanced health awareness[147] Corporate Governance and Social Responsibility - The company emphasizes the importance of ESG principles, focusing on environmental protection, social responsibility, and governance, particularly after its listing on the Beijing Stock Exchange in November 2021[136] - The company has established a robust governance structure, adhering to laws and regulations, and has committed to enhancing its internal control systems following its listing on the Beijing Stock Exchange[142] - The company has been recognized for its leadership in poverty alleviation efforts, with its chairman awarded for outstanding contributions in this area[134] Intellectual Property and Innovation - The company holds a total of 52 patents, including 49 invention patents, maintaining its focus on innovation and development in biotechnology[122] - The company emphasizes the importance of intellectual property protection, with a high percentage of its patents valued above 8 points, indicating strong patent value in the antiviral drug sector[58] - The company has obtained invention patent authorization for key technologies involved in its hepatitis treatment products, positioning itself at an industry-leading level[128] Clinical Trials and Product Development - The company has initiated a Phase III clinical trial for the nebulized inhalation treatment of pediatric RSV pneumonia, achieving 80% enrollment completion across 28 clinical research centers[60] - The company is also conducting a Phase III clinical trial for the treatment of COVID-19 pneumonia, collaborating with five designated treatment centers and adapting the trial protocol based on the evolving characteristics of the virus[61] - The company has successfully designed an adaptive clinical trial protocol for the new PEG-integrated interferon mutant injection for hepatitis B, with plans to conduct trials at 15 clinical centers nationwide[71] Shareholder and Equity Information - The total number of ordinary shares outstanding is 121,810,000, indicating a substantial equity base for the company[29] - The controlling shareholder is Beijing Southeast Pharmaceutical Investment Holding Co., Ltd., with actual controllers being Cheng Yongqing, Yin Xiaoming, and Cheng Shiqing[29] - The company declared a cash dividend of CNY 2.18 per 10 shares on May 21, 2021, with no stock bonus or capital increase[198]